Business
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027Process underway to reactivate global sites for MAGNITUDE-2 Phase 3 clinical trial of nex-z in ATTRv-PN; enrollment completion expected in second half of 2026FDA engagement ongoing to resolve clinical hold on MAGNITUDE Phase 3 clinical trial of nex-z in ATTR-CM Ended 2025 with approximately $605 million in cash, cash equivalents and marketable s
About this update from Intellia Therapeutics, Inc.
[{"type":"image","alt":"Intellia Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Intellia Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/e17fcc014402640b19141cf9f933532d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DZg.lk3JYo_QYqp_MgL6yw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e17fcc014402640b19141cf9f933532d","width":300,"height":150}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027","length":153,"tagName":"p"}]},{"val":[{"type":"text","content":"Process underway to reactivate global sites for MAGNITUDE-2 Phase 3 clinical trial of nex-z in ATTRv-PN; enrollment completion expected in second half of 2026","length":158,"tagName":"p"}]},{"val":[{"type":"text","content":"FDA engagement ongoing to resolve clinical hold on MAGNITUDE Phase 3 clinical trial of nex-z in ATTR-CM ","length":103,"tagName":"p"}]},{"val":[{"type":"text","content":"Ended 2025 with approximately $605 million in cash, cash equivalents and marketable securities; expected to fund operations into the second half of 2027 ","length":152,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":566,"olType":false},{"type":"text","content":"CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the fourth quarter and year ended December 31, 2025.","length":338,"tagName":"p"},{"type":"text","content":"“2025 was a time of accomplishment and resiliency for Intellia as we presented encouraging longer term Phase 1/2 clinical data for both lonvo-z and nex-z, rapidly enrolled patients in our three Phase 3 trials, commenced activities to prepare for a potential lonvo-z launch in HAE and responded to the clinical holds on our nex-z Phase 3 trials late in the year,” said Intellia President and Chief Executive Officer John Leonard, M.D. “We expect the year ahead to be a pivotal one, highlighted by our topline P...